Journal article
Candidemia following solid organ transplantation in the era of antifungal prophylaxis: The Australian experience
SJ Van Hal, DJE Marriott, SCA Chen, Q Nguyen, TC Sorrell, DH Ellis, MA Slavin
Transplant Infectious Disease | WILEY-BLACKWELL PUBLISHING, INC | Published : 2009
Abstract
Solid organ transplant (SOT) recipients have high rates of invasive fungal infections, with Candida species the most commonly isolated fungi. The aim of this study was to identify differences between incidence rates, risk factors, clinical presentations, and outcomes of candidemia in SOT recipients and non-SOT patients. Data from the multicenter prospective Australian Candidaemia Study were examined. From August 2001 to July 2004, 24 episodes (2.2%; 24/1068) of candidemia were identified in SOT recipients. During this period, the numbers of transplanted organs included liver (n=455), kidney (n=1605), single lung (n=57), bilateral lung (n=183), heart and lung (n=18), heart (n=157), and pancre..
View full abstractGrants
Funding Acknowledgements
We wish to acknowledge all the members of the Australian Candidaemia Study (details can be found in reference [12]). The study was supported by a grant from Pfizer Australia. D. Marriott has been on antifungal advisory boards of Schering-Plough, Pfizer, and Merck Sharp and Dohme, Australia. S.C.A Chen is/has been on the antifungal advisory boards of Pfizer Australia and Gilead Sciences. M. Slavin declares current or past Advisory Board membership of Pfizer, Merck Sharp and Dohme, Schering-Plough, and Gilead, and receipt of research grants from Pfizer, Merck Sharp and Dohme, Schering-Plough, and Gilead Sciences.